Botch Promotes Neurogenesis by Antagonizing Notch

Zhikai Chi,1,2 Jianmin Zhang,2,3 Akinori Tokunaga,2,3 Maged M. Harraz,2,3 Sean T. Byrne,2,5 Andrew Dolinko,2 Jing Xu,1 Seth Blackshaw,1,2 Nicholas Gaiano,1,2,3,4 Ted M. Dawson,1,2,3,6,* and Valina L. Dawson1,2,3,5,6,*

1Solomon H. Snyder Department of Neuroscience
2Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering
3Department of Neurology
4Department of Oncology
5Department of Physiology
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

*These authors contributed equally to this work
*Correspondence: tdawson@jhmi.edu (T.M.D.), vdawson@jhmi.edu (V.L.D.)
DOI 10.1016/j.devcel.2012.02.011

SUMMARY
Regulation of self-renewal and differentiation of neural stem cells is still poorly understood. Here we investigate the role of a developmentally expressed protein, Botch, which blocks Notch, in neocortical development. Downregulation of Botch in vivo leads to cellular retention in the ventricular and subventricular zones, whereas overexpression of Botch drives neural stem cells into the intermediate zone and cortical plate. In vitro neurosphere and differentiation assays indicate that Botch regulates neurogenesis by promoting neuronal differentiation. Botch prevents cell surface presentation of Notch by inhibiting its processing and trafficking.

INTRODUCTION
Among the proteins and signal cascades that participate in building the complex architecture of the brain from neural progenitors cells (Ayala et al., 2007; Doe, 2008), Notch signaling is prominent (Kopan and Ilagan, 2009; Louvi and Artavanis-Tsakonas, 2006). Notch maintains cells in the neuronal progenitor fates by inhibiting neuronal differentiation and promoting gliogenesis. Notch is a highly evolutionarily-conserved signaling pathway controlling cell fate decisions, differentiation, proliferation, and apoptosis both during development and in adult tissues (Artavanis-Tsakonas et al., 1999; Kopan and Ilagan, 2009). Due to the emerging role of Notch signaling in health and disease, understanding the regulation and actions of the Notch pathway is developing clinical interest and importance.

Although regulating functionally diverse physiologic outcomes, the canonical core Notch pathway remains constant (Selkoe and Kopan, 2003). In mammals the Notch pathway consists of Notch 1–4, Delta-like ligands (Dlls) 1, 3, and 4, and Jagged ligands (J1, J2). Immature Notch is processed by cleavage by a furin-type protease to form a mature heterodimeric receptor. Notch is localized to the surface of cells where it interacts with its ligands, Dll 1, 3, 4, J1, and J2. On binding of ligands, Notch is rendered susceptible to a series of proteolytic steps, first by the ADAM family metalloproteases then an intramembrane cleavage by the γ-secretase complex (Ilagan and Kopan, 2007). These ligand-dependent cleavage events eventually promote the release of the Notch intracellular domain (NICD) from the plasma membrane. NICD translocates to the nucleus, where it converts the C-promoter binding factor-1 (CBF-1) complex from a transcriptional repressor to a transcriptional activator resulting in expression of Notch target genes. This represents the “canonical” or core signaling pathway. However, recent work is defining additional, noncanonical, points of regulation of Notch activity.

Many developmental processes are extremely sensitive to the dosage of Notch signaling (Donoviel et al., 1999; Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004; McCright et al., 2002). Thus, Notch signaling pathways must be precisely modulated and regulated in order for Notch to choreograph the complex events of development. Here we describe and characterize neuroprotective gene 7 (NPG7), which we rename Botch (Blocks Notch), that promotes neurogenesis by downregulating the Notch signaling pathway. The mechanism by which Botch inhibits Notch1 is through interfering with its processing and trafficking.

RESULTS
Botch Is Developmentally Expressed
NPG7 (EF688602), Botch was identified in functional screen for neuroprotective proteins (Dai et al., 2010). Botch is a protein of unknown function. Sequence analysis reveals Botch homologs in Drosophila, C. elegans, chickens, rodents, and man (see Figure S1 available online). It is a 24.5 kDa protein of 223 amino acids in mouse (NM_026929) and human (NM_024111) and 222 amino acids in rat (NM_001173437), Botch has no known mammalian protein domains and no closely related mammalian homolog. Botch is distantly related to ChaC, a protein that is...
Figure 1. Botch Is Developmentally Expressed and Localized to the Golgi

(A) Northern analysis of Botch in adult mouse tissues.
(B) Immunoblot analysis of mouse brain with the Botch monoclonal antibody. Optical densitometry measurements were normalized to β-tubulin (bottom).
(C) Whole-mount Botch in situ hybridization of E9.5 mouse. Arrowhead, dorsal aorta; arrow, heart.
(D) Immunostaining with anti-Botch antibody for endogenous Botch in E12.5 mouse forebrain cortex. Scale bar, 10 μm.
(E) Immunoblot analysis of regional mouse brain tissue at E12.5, E14.5, and E16.5 with the Botch monoclonal antibody. Optical densitometry measurements were normalized to β-tubulin (bottom).
(F) Immunoblot analysis of regional mouse brain tissue at E12.5, E14.5, and E16.5 with the Botch monoclonal antibody. Optical densitometry measurements were normalized to β-tubulin (bottom).
thought to be associated with the putative ChaA Ca$^{2+}$/H$^+$ cation transport protein in Escherichia coli. The gene is currently annotated as ChaC1, although there is no evidence for such a function in mammalian cells. It is induced by the unfolded protein response and is thought to play a role in cell survival (Mungrue et al., 2009).

By northern blot analysis Botch message is about 1.8 kb in mouse, and it is widely expressed in multiple organs including the brain (Figure 1A). A monoclonal antibody was raised to Botch (NeuroMab, Davis, CA, USA) that recognizes a single band on immunoblot, the signal of which is reduced following shRNA-mediated knockdown of Botch (Figures S2A, S2B, S2D, and S2E), indicating that the antibody is specific for Botch. By immunoblot analysis Botch is heterogeneously distributed throughout the adult mouse brain (Figure 1B). Whole-mount in situ hybridization at E9.5 reveals that Botch is highly expressed in mouse forebrain and anterior spinal cord and moderately expressed in the dorsal aorta and heart (Figure 1C). Endogenous Botch is detected in E12.5 mouse forebrain cortex by immunohistochemistry (Figure 1D). Expression of Botch message in adult brain by in situ hybridization is much lower than expression during development; therefore, immunoblot analysis was performed at different embryonic stages (E12.5, E14.5, E16.5), and the relative expression levels of Botch were compared in the cortex, ganglionic eminence, and septum (Figure 1E). E14.5 cortex expresses the high levels of Botch, and Botch is also expressed at relatively high levels in the germinal zones including the ganglionic eminence and septum at E14.5. Levels in these areas decrease at E16.5. High-resolution z stack confocal immunohistochemistry of cultured HEK293 cells or primary neuronal precursor cultures from E14.5 ganglionic eminence indicates that Botch colocalizes with the trans-Golgi marker (TGN38), but not the cis-Golgi marker (GM130), indicating that in the Golgi, Botch resides in the trans-Golgi (Figure 1F). Botch does not colocalize with the endocytic markers Caveolin-1, Clathrin, EEA1, or Rab5 (data not shown). Subcellular fractionation by sucrose gradient for the Golgi fractionation shows Botch enrichment in the Golgi fraction similar to the Golgi marker, GM130 (Figure 1G). We cannot exclude the possibility that Botch may be localized to other subcellular cytoplasmic compartments, but these results indicate that Botch is localized to the trans-Golgi where it could mediate it biological actions.

**Botch Regulates Embryonic Neurogenesis In Vivo**

Because Botch is expressed at high levels during development and is enriched in the germinal zone of the forebrain, gain- and loss-of-function studies were performed to explore the role of Botch in neocortical development. In utero coelectroporation of pCAG-EGFP and pCAG-Botch into E13.5 CD-1 mouse brains was performed (Figures 2A–2C). Embryos were harvested at E15.5 and immunostained for GFP to identify Botch-overexpressing cells and counterstained with DAPI to identify all cells.

Botch overexpression resulted in fewer GFP+ cells in the ventricular (VZ) and subventricular zones (SVZs) and more cells in the cortical plate (CP) and intermediate zone (IZ) when compared to coelectroporation of pCAG-EGFP with Mock control (pCAG empty vector) (Figures 2A–2C), suggesting that Botch could promote neurogenesis.

To explore loss of function, a shRNA was designed to knock down expression of Botch. Expression constructs were generated from a bicistronic construct pCAG-EGFP (Niwa et al., 1991) with U6 driving shRNA-Botch or shRNA-DsRed and CAG promoter driving EGFP (Figure 2A). The shRNA was targeted toward a region of Botch conserved between mouse and rat (Figure S2A). A shRNA-resistant Botch was also generated (mtBotch) (Figure S2A). shRNA-Botch is effective in knocking down transiently expressed wild-type (WT) Botch in HEK293 cells (Figure S2B), whereas it is ineffective in knocking down mtBotch (Figure S2C). In ganglionic eminence cultures shRNA-Botch knocks down endogenous Botch (Figures S2D–S2F). shRNA to DsRed (Duan et al., 2007), which engages the RISC complex, serves as an additional control and has no effect on overexpressed or endogenously expressed Botch (Figures S2B–S2E).

To explore the role of Botch in neurogenesis, in utero electroporation of shRNA-DsRed, shRNA-Botch, shRNA-Botch and Botch, or shRNA-Botch and mtBotch into E13.5 CD-1 mouse brains was performed, and embryos were harvested at E15.5 (Figures 2D and 2E). Knockdown of Botch greatly increases the percentage of cells in the VZ and SVZ while significantly decreasing the percentage of GFP+ cells in the CP and IZ (Figures 2D and 2E). Coexpression of WT Botch, which is sensitive to shRNA-Botch, does not alter the shRNA-Botch phenotype, but coexpression of mtBotch, which is not susceptible to knockdown by shRNA-Botch, rescues the knockdown phenotype (Figures 2D and 2E).

The number of Tbr1+ (T-box brain 1) cells (an indicator of neuronal differentiation) was assessed following in utero electroporation of Botch or shRNA-Botch or rescue of shRNA-Botch with mtBotch (Figures 2F–2I) to evaluate Botch regulation of neurogenesis. Overexpression of Botch increases the number of Tbr1+ and GFP+ cells implying regulation of neurogenesis rather than mispositioned progenitor cells from altered migration (Figures 2F and 2G). Conversely, knockdown of Botch results in a loss of Tbr1+ expression in GFP+ cells indicating suppression of neurogenesis, which can be rescued by expression of mtBotch (Figures 2H and 2I). Furthermore, GFP+ cells are either Pax6+ in the VZ (Figure S2G) or Tbr2+ in the SVZ (Figure S2H) but are Tbr1− in both cases (Figure 2H). There is no alteration in the glial marker GFAP (Figure S2I). Nestin immunohistochemistry reveals intact radial-glial scaffolds in neocortex following electroporation with shRNA-Botch (Figure S2J). Active caspase-3 immunohistochemistry confirms that the altered cellular distribution pattern is not due to apoptosis, following knockdown of

---

(F) Immunohistochemical subcellular localization of Botch with the Botch monoclonal antibody compared to the trans-Golgi marker (TGN38) and the cis-Golgi marker (GM130) in HEK293 or primary ganglionic eminence cultures. Colocalization is represented by yellow in the Merge panels with z stack.

(G) Immunoblot analysis of sucrose gradient Golgi fractions from E15.5 mouse forebrains. GM130 was used as a Golgi marker because sucrose gradient enrichment does not separate cis-Golgi from trans-Golgi.

All experiments were repeated three times in (C)–(G).

See also Figure S1.
Figure 2. Botch Regulates Embryonic Neurogenesis In Vivo

(A) A schematic diagram of pCAG constructs for overexpression (gain of function) or knockdown (loss of function) for in utero injection and electroporation.

(B–I) Distribution of GFP+ cells 2 days after in utero injection and electroporation.

(B) Representative confocal images of cortex immunostained for GFP with and without the DAPI channel with Botch expression. CP, cortical plate; IZ, intermediate zone; VZ, ventricular zone; SVZ, subventricular zone.

(C) Quantification of distribution of GFP+ cells in (B). Values represent the mean ± SEM (n = 4; **p < 0.01; ***p < 0.001, Student’s t test).

(D) Representative confocal images of cortex immunostained for GFP with and without the DAPI channel following knockdown of Botch and rescue with mtBotch.

(E) Quantification of distribution of GFP+ cells in (D). Values represent the mean ± SEM (n = 3; **p < 0.01; nonsignificant [n.s., p > 0.05; one-way ANOVA, posttest: Tukey’s multiple comparison test).

(F) Representative confocal images of GFP+ (green) and Tbr1+ (red) in cortex following Botch expression. The box represents the source of the high-power image (magnification 45x). White dots define the boundaries of IZ.
Botch (Figures S2K and S2L). Taken together, these data indicate that Botch regulates neurogenesis, not migration or altered cell viability.

Embryos were harvested at E17.5 to observe the role of Botch on a later stage of neuronal development. Knockdown of Botch greatly increases the number of cells in the VZ, SVZ, and IZ while significantly decreasing the number of GFP+ cells in the CP. mtBotch rescues the knockdown phenotype (Figures S2M and S2N). Thus, Botch appears to regulate neocortical neurogenesis and may direct the proliferating-zone exit of neural stem cells (NSCs).

**Botch Inhibits the Notch Signaling Pathway**

Notch activation results in observations that are similar to the effects of shRNA-Botch suggesting a potential interaction (Mizutani and Saito, 2005; Mizutani et al., 2007). Thus, HeLa cells were transfected with full-length Notch1 (Notch1-FL), and 4x wtCBF-1-response-element luciferase reporter, β-galactosidase reporter (β-gal), and different concentrations of a Botch expression construct (Hsieh et al., 1996). HeLa cells were cocultured 48 hr later with NIH 3T3 cells expressing the Notch ligand DIl1 or J1, or mock control. β-gal and luciferase activity was determined 24 hr after coculture. Botch significantly inhibits the activation of CBF-1-dependent Notch1 activity in a dose-dependent manner (Figure 3A). To evaluate the specificity of this interaction, a CBF-1 transactivation inactive mutant reporter was used (Hsieh et al., 1996) with no difference observed between Botch and the controls (Figure 3B). HeLa cells transfected with full-length Notch2, Notch3, or Notch4 and 4x wtCBF-1-response-element luciferase reporter, β-gal, and different concentrations of Botch expression constructs (Figures S3A–S3C) display a dose-dependent botch inhibition of CBF-1-dependent Notch2, Notch3, or Notch4 activity (Figure S3A–S3C). The γ-secretase inhibitor, DAPT, inhibits CBF-1-dependent Notch signaling, serving as a positive control for the specificity of this Notch reporter assay (Figure 3C).

The effect of gain or loss of function of Botch on the expression of Notch target genes, Hes1 and Hes5, was evaluated in E14.5 ganglionic eminence neural precursor cultures by quantitative real-time PCR analysis (Iso et al., 2003). Overexpression of Botch leads to the downregulation of Hes1 and Hes5 mRNA. Knockdown of Botch has the opposite effect leading to an upregulation of Hes1 and Hes5 mRNA (Figure 3D), an effect that is rescued by expression of mtBotch. (Figure 3D). In ganglionic eminence cultures from the transgenic Notch reporter (TNR) mice (Mizutani et al., 2007), overexpression of Botch leads to a decrease of endogenous GFP signal, indicating decreased Notch signaling (Figures 3E and 3F). Cleaved Notch1 is also decreased as detected by an antibody recognizing γ-secretase-cleaved Notch1 (V1744; Cell Signaling Technology, Beverly, MA, USA) (Figures 3E and 3F). These results indicate that Botch through inhibiting Notch signaling can regulate the expression of Notch target genes.

Knockdown of Botch affects endogenous Notch signaling because there is a 4-fold increase of cleaved Notch1 immunoreactivity (V1744) in shRNA-Botch cells compared with shRNA-DaRed cells in vivo. This effect is rescued by expression of mtBotch (Figures 3G and 3H). To determine whether Botch influences Notch signaling in simple organisms, S2 Drosophila cells were transfected with full-length Drosophila Notch-VP16 (pANLV) (Saj et al., 2010). NRE luciferase reporter or NRE mutant luciferase reporter (Furriols and Bray, 2001), β-gal, and a Drosophila Botch expression construct. β-gal and luciferase activity was measured 24 hr later. In pANLV-transfected S2 cells, Botch significantly inhibits the activation of Notch activity (Figure 3I). These data indicate that Botch inhibition of Notch signaling might be evolutionarily conserved.

**Botch and Notch Are Expressed in a Similar Temporal and Spatial Pattern**

For Botch to regulate Notch signaling during development, both proteins would need to be expressed in a similar temporal and spatial pattern. In situ hybridization reveals an overlapping expression pattern for Botch and Notch1 at E12.5, E14.5, and E16.5 (Figure S4A). By immunohistochemical analysis there is a partial intracellular colocalization of Botch with Notch in Hek293 cells, HeLa cells, primary cultures of ganglionic eminence, and primary cultures of hippocampus (Figures S4B–S4E). Thus, it is spatially and temporally possible for Botch to regulate Notch signaling.

**Botch Interacts with the Notch1 Extracellular Domain**

To evaluate whether Botch can physically interact with Notch in vivo, a coimmunoprecipitation was performed from E14.5 ganglionic eminence lysates. Surprisingly, Botch immunoprecipitation pulls down more of the uncleaved immature full-length form of Notch1 than the transmembrane and intracellular (TMIC) domain, which is the S1-cleaved mature form of Notch and also the dominant form of Notch in the input (Figure 4A). This interaction is specific because Notch1 immunoreactivity is absent in the IgG immunoprecipitation control and following immunosorption with excess Botch (Figure 4A). Furthermore, Botch does not coimmunoprecipitate the EGF repeat-containing protein DIl1, nor does it bind to other membrane receptors including EGFR or FGFR2 (Figure 4B). Botch is a 25 kDa protein, and it migrates closely with the antibody light chain and thus is not readily discriminated from the light chain on immunoblot analysis or by Coomassie staining. To show that Botch immunoprecipitation indeed immunoprecipitates Botch, overexpressed Botch-myc was immunoprecipitated by the Botch antibody, and immunoblot analysis indicates that the Botch antibody is capable of immunoprecipitating Botch (Figure S4F).

Coimmunoprecipitation experiments show that Botch interacts with the extracellular domain of Notch1 (NECD1) (Figure 4C), but not the intracellular domain (NICD1) (Figure 4D). To further refine the binding site on Notch1, NEC1D was evenly divided...
Figure 3. Botch Inhibits the Notch Signaling Pathway

(A) wtCBF-1 luciferase reporter assays of HeLa cells expressing Notch1 and different concentrations of Botch cocultured with NIH 3T3 cells expressing Notch ligands. wtCBF-1 luciferase activity was normalized to β-gal activity and then to the Mock group without Botch. Values represent the mean ± SEM (n ≥ 3; forDll1 group, **p < 0.01, one-way ANOVA; for J1 group, *p < 0.01, one-way ANOVA, posttest: Tukey’s multiple comparison test).

(B) mtCBF-1 luciferase reporter assays of HeLa cells expressing Notch1 and Botch cocultured with NIH 3T3 cells expressing Notch ligands. mtCBF-1 luciferase activity was normalized to β-gal activity and then to the Mock group without Botch. Values represent the mean ± SEM (n ≥ 3, n.s., p > 0.05, Student’s t test).

(C) wtCBF-1 luciferase reporter assays of HeLa cells expressing Notch1 cocultured with NIH 3T3 cells expressing Notch ligands in the presence of DMSO or DAPT. wtCBF-1 luciferase activity was normalized to β-gal activity and then to the Mock group with DMSO. Values represent the mean ± SEM (n ≥ 3; **p < 0.01, Student’s t test).
into four fragments containing EGF repeats 1–12, 11–24, 22–33, and 32–36 with Lin12/Notch repeats (LNRs), respectively, with each fragment also expressing the 20 amino acid signal peptide from Notch1 for proper subcellular localization. These four constructs encode rat Notch1 amino acids 1–493, 482–910, 832–1,310, and 1,224–1,723, respectively. Botch binds to the construct containing EGF repeats 32–36 with LNR (Figure 4E).

The EGF repeats 32–36 with LNR were further subdivided. Botch binds to the LNR-GFP containing the LNR and HD domain (heterodimerization domain) (rat Notch1 amino acids 1,449–1,723), but not to the fragment containing EGF repeats 32–36 (rat Notch1 amino acids 1,224–1,448) (Figure 4F). Because LNR-GFP also contains the S1 cleavage sites, the ability of Botch to bind to Notch1 versus the S1 cleavage-resistant Notch1 (Notch1-Loopout, Flag-N1-Ga4-LO) (Gordon et al., 2009) was investigated. Botch binds to Notch1, but not to Notch1-Loopout (Figure 4G). Thus, Botch does not bind to either EGF-like repeats or the LNR, but it specifically binds to the S1 furin-like cleavage site.

The binding properties of Botch to Notch were ascertained by using an alkaline phosphatase-tagged Botch (Botch-N-AP) (Chapman et al., 2006; Flanagan and Cheng, 2000). Notch1 was transiently transfected into HEK293 cells, and lysates were immunoprecipitated with anti-Notch1 antibody (Santa Cruz Biotechnology) and protein G beads. Binding affinity was determined by incubating different concentrations of Botch-N-AP fusion protein with an equal volume of Notch1 binding protein G beads. Botch binds to Notch1 in a saturable manner with a binding affinity of 3.3 nM (Figure 4H). Botch also binds with varying affinity to Notch2 (8.8 nM), Notch3 (3.3 nM), and Notch4 (6.3 nM) (Figures S4G–S4I). These results in combination indicate that Botch binds to Notch with the strongest interaction with Notch1 and Notch3.

Botch Interferes with Processing of Notch1 to Its Mature Form

Whole-cell and cell surface expression of Botch and Notch were monitored in neural precursor cells during differentiation into neuronal cultures. Botch expression increases and Notch surface expression decreases during differentiation (Figures 5A and 5B). To further investigate the actions of Botch on Notch, Botch and Flag-Notch1-GFP constructs were overexpressed in HEK293 cells to monitor Notch1 processing. The effects of Botch were compared to the furin inhibitor, DEC-RVKR-CMK. Overexpression of Botch and the furin inhibitor, DEC-RVKR-CMK, leads to an approximately 2-fold increase in the level of unprocessed Notch1-Fc with a significant decrease in processed NEC1 (Figures 5C and 5D). Biotin surface labeling of Notch1 under identical conditions shows an 80% reduction of surface Notch1 (Figures 5C and 5D). By FACS analysis binding of the Fc-tagged Notch1 ligand J1-Fc was significantly reduced with expression of Botch (Figure 5E). To confirm that Botch requires Notch1-FL to mediate its inhibitory effects, the NICD1 and Notch1 extracellular domain deleted form (Notch1-DeltaE-GFP), as the constitutively active forms of Notch1, were overexpressed in HeLa cells, and Notch1 activity was monitored by the CBF-1 luciferase reporter assay (Figures 5F and 5G). Botch has no effects on the abilities of NICD1 or Notch1-DeltaE to activate the CBF-1 luciferase reporter, indicating that the actions of Botch on Notch1 occur before Notch1 cleavage induced by ligand-receptor binding and NICD1 signaling.

Because furin is required for Notch1 S1 processing (Kopan and Ilagan, 2009; Louvi and Artavanis-Tsakonas, 2006), an in vitro furin cleavage assay was performed to test whether Botch regulates S1 cleavage (Figure 5H). Immunoprecipitated Flag-Notch1-GFP was evenly divided into three groups. The first group was pretreated with AP, and then treated with furin and DMSO. The second group was pretreated with AP, and then treated with furin in the presence of furin inhibitor, DEC-RVKR-CMK (Enzo Life Sciences). The last group was pretreated with Botch-AP, and then treated with furin and DMSO. Botch blocks furin cleavage in a manner similar to the furin inhibitor, DEC-RVKR-CMK (Figure 5H). Thus, Botch maintains Notch1 in an immature form primarily by blocking the S1 furin-like cleavage of Notch, although we cannot exclude the possibility that Botch also retains full-length Notch in the Golgi preventing its trafficking.

HEK293 cells were cotransfected with the EGF repeat-containing protein DII1-GFP and Botch-myc followed by immunoprecipitation. Botch does not interact with DII1 (Figure S5A). Binding studies indicate that there is no interaction between Botch and DII1 (Figure S5B), and analysis of surface expression of DII1 shows that Botch does not alter the expression of DII1 (Figures SSC and SSD). Additionally, Botch does not alter the surface expression of the unrelated glutamate receptor protein subunits, GluR2 or NR2A, as well as the Notch1 ligand Jagged1 (Figures S5E–S5J). Taken together, these data indicate that Botch is not binding indiscriminately to any EGF repeat-containing protein or receptor protein, but Botch shows selectivity for Notch proteins. Moreover, Botch’s affects on Notch1 surface expression does not appear to be due to a generalized defect in the trans–Golgi network because Botch has no effect on the surface expression of other membrane receptors.

(D) Real-time PCR results of Botch, Hes1, and Hes5 mRNA from E14.5 ganglionic eminence cultures following gain of function (GOF) with Botch overexpression, loss-of-function group (LOF) with shRNA-Botch knockdown, and rescue with mtBotch. For GOF the control is empty pCAG vector and for LOF is shRNA-DsRed.

See also Figure S3.
such as the glutamate NR2A or GiuR1 receptors, nor does it have any effect on the trafficking of Delta1 or Jagged1.

**Botch Promotes C2C12 Differentiation by Inhibiting the Notch Signaling Pathway**

The role of Botch in antagonizing Notch1 was explored in a classic model of Notch signaling of C2C12 cell differentiation to myotubes (Lindsell et al., 1995). C2C12 cells stably expressing Notch1 (C2C12-N1) (Chapman et al., 2006) were transiently transfected with an 8x wtCBF-1-response-element luciferase reporter, a β-gal, and a Botch expression construct. C2C12-N1 cells were cocultured 48 hr later with NIH 3T3 cells expressing the Notch ligands Dll1 or J1, or mock control. In addition, the effects of Botch on cocultured WT C2C12 and C2C12-N1 cells were also monitored. Botch significantly inhibits Notch activity (Figure 6A). Myotube differentiation was monitored by myosin heavy-chain (MHC) immunostaining in C2C12 cells overexpressing Botch, and compared to control C2C12 cells overexpressing GFP (Figure 6B) and quantified (Figure 6C) (Chapman et al., 2006). Botch leads to an approximately 3-fold increase of MHC+ cells in WT, C2C12, or C2C12-N1 cells (Figure 6C). Coculture of C2C12-N1 cells with NIH 3T3 expressing Dll1 or J1 almost completely inhibits the expression of MHC. However, overexpression of Botch reverses the inhibition of ligand-dependent Notch activation, leading to an increase in MHC+ cells (Figure 6C). The γ-secretase inhibitor, DAPT, which blocks Notch signaling, increases the number of MHC+ cells in a manner similar to Botch (Figure 6D). There is no additional effect with overexpression of Botch indicating that both DAPT and Botch are acting in the same pathway. Overexpressing NICD1 overrides the Botch inhibitory effects on Notch signaling, consistent with the notion that Botch is acting upstream of ligand-receptor binding (Figure 6E). At day 3 there is increased expression of the early differentiation marker myogenin

![Figure 4. Botch Preferentially Interacts with the NECD1](image)

(A) Immunoblot of coimmunoprecipitation of endogenous uncleaved immature full-length (FL) Notch1 by an anti-Botch polyclonal antibody (Botch-PoAb) from E14.5 ganglionic eminence. An unrelated rabbit IgG antibody and preabsorption of the Botch-PoAb with recombinant Botch-GST are negative controls. IP, immunoprecipitation; FL, full-length; TMIC, transmembrane and intracellular domain.

(B) Immunoblot of coimmunoprecipitation with Botch-PoAb and Dll1, EGFR or FGRF2 from E14.5 ganglionic eminence. (C and D) Immunoblots of Botch coimmunoprecipitation with the NICD1 or the NECD1. (E) Immunoblot for GFP of Botch coimmunoprecipitation with four fragments of the NECD1; EGF repeats 1–12, 11–24, 22–33, and 32–36 with LNRs that encode rat Notch1 amino acids 1–493, 482–910, 832–1,310, and 1,224–1,723 with cDNA encoding the 20 amino acid signal peptide from Notch1 at the N-terminal for proper subcellular localization.

(F) Immunoblot for GFP of Botch coimmunoprecipitation with fragments containing EGF repeats 32–36 and LNR divided into EGF repeats 32–36 (rat Notch1 amino acids 1,224–1,448) or the LNRs (rat Notch1 amino acids 1,449–1,723) with cDNA encoding the 20 amino acid signal peptide from Notch1 at the N-terminal for proper subcellular localization.

(G) Coimmunoprecipitation of Botch with Notch1 (Flag-N1-Gal4) or Notch Loop Out (Flag-N1-Gal4-LO), which lacks the S1 cleavage sites, visualized by immunoblot. Flag-N1-Gal4-LO lacks of amino acid sequence 1,624–1,670 in human Notch1.

(H) Scatchard plot of quantitative binding of Botch-N-AP to Notch1 immobilized by anti-Notch1 on protein G Sepharose beads. Experiments were repeated three times with similar results in (A)–(H).

See also Figure S4.
Botch Promotes Embryonic Neurogenesis by Inhibiting the Notch Signaling Pathway

NICD or the dominant-negative version of the coactivator MAML (DN-MAML-EGFP) (Figure 6G), which forms a transcriptionally inactive complex with NICD to produce loss of Notch signaling (Maillard et al., 2004), was expressed with Botch in utero. NICD blocks Botch repression of Notch signaling (Figures 6H and 6I). In the presence of DN-MAML-EGFP, Botch has no effect (Figures 6H and 6I). Knockdown of Botch greatly increases the percentage of cells in the VZ and SVZ while significantly decreasing the percentage of GFP+ cells in the CP and IZ (Figure 6J), an effect that is reversed by reduction of Notch signaling through expression of DN-MAML-EGFP (Figures 6J and 6K) in which normal cellular distribution is restored. Additionally, knockdown of Botch and inhibition of Notch signaling by expression of DN-MAML are not synergistic when compared with inhibition of Notch signaling alone (Figures 6J and 6K). Taken together, these results suggest that Botch and Notch are acting in the same pathway to regulate embryonic neurogenesis.

Botch Promotes Neurogenesis by Regulating Cell Fate Choices In Vitro

An important feature of neural precursor cells is the capacity for self-renewal that is mediated in part by Notch signaling; therefore, the actions of Botch were evaluated in neurosphere cultures established from the lateral and medial ganglionic eminences of E14.5 CD-1 mouse embryos. Botch expression decreases neurosphere frequency as compared to empty vector (Figures 7A and 7B). The γ-secretase inhibitor factor 18 (GSI...
Figure 6. Botch Promotes C2C12 Differentiation and Embryonic Neurogenesis by Inhibiting the Notch Signaling Pathway

(A) wtCBF-1 luciferase reporter assays with Mock or Botch-transfected C2C12 WT cells, C2C12-Notch1 cells, and C2C12-Notch1 cells cocultured with NIH 3T3 cells expressing Notch ligands. wtCBF-1 luciferase activity was normalized to β-gal activity and to the Mock. Values represent the mean ± SEM (n ≥ 3; **p < 0.01, Student’s t test).

(B) Representative confocal images of either GFP or Botch-transfected C2C12 cells immunostained for MHC, GFP or Botch and counterstained for DAPI.

(C) Differentiation assays in either GFP or Botch-transfected WT C2C12 cells, C2C12-Notch1 cells or C2C12-Notch1 cells cocultured with NIH 3T3 cells expressing different Notch ligands. Percentages of MHC+ cells are shown. Values represent the mean ± SEM (n ≥ 3; *p < 0.05; **p < 0.01, Student’s t test).

(D) Differentiation assays in GFP or Botch-transfected C2C12 WT cells in the presence of DMSO or γ-secretase inhibitor DAPT. Percentages of MHC+ cells are shown. Values represent the mean ± SEM (n ≥ 3; n.s., p > 0.05, Student’s t test).
FXVIII) that blocks Notch signaling (Dang et al., 2006) also results in decreased neurosphere frequency similar to Botch (Figure 7B). In vivo shRNA-Botch knockdown results in an increase in brain lipid binding protein (BLBP) expression, a marker for early radial glia, which is rescued by expression of mtBotch (Figures 7C and 7D). These data are consistent with our previous report that Notch signaling induces BLBP expression and that BLBP is a Notch target (Anthony et al., 2005; Gaiano et al., 2000).

The developmental potential of neural precursor cells (Mizutani et al., 2007) in adherent cultures from E14.5 CD-1 mouse ganglionic eminences was evaluated by immunostaining for Tuj1 to identify neuronal fate choices and GFAP for glial ones. Gain- and loss-of-function experiments of Botch were conducted. Botch overexpression leads to an approximately 3-fold increase in the number of Tuj1+ cells and a corresponding reduction in the GFAP+ cells (Figures 7E and 7F). In contrast, knockdown of Botch by shRNA leads to a 3-fold reduction in Tuj1+ cells and a significant increase in the number of GFAP+ cells (Figures 7G and 7H). The γ-secretase inhibitor DAPT is effective in reversing the effects of Botch knockdown on glial fate choice, indicating that the enhanced glial cell fate following shRNA knockdown of Botch is due to Notch signaling (Figure 7H). These experiments taken together indicate that Botch promotes embryonic neuronal differentiation by inhibiting Notch signaling.

**DISCUSSION**

Here we characterize Botch as an inhibitor of Notch1 signaling that promotes embryonic neurogenesis. In both mammals and fruit flies, Notch signaling plays a critical role in regulating self-renewal and differentiation of NSCs (Louvi and Artavanis-Tsakonas, 2006). NICD1 keeps NSCs in the proliferation zones (Mizutani and Saito, 2005; Mizutani et al., 2007), whereas knockdown of CBF-1 drives NSCs into the IZ and CP (Mizutani et al., 2007). In contrast, Botch drives more cells to the IZ and CP, whereas downregulation of Botch tends to keep cells in the proliferating zones, indicating that Botch is acting in opposition to Notch.

The neurogenic phenotypes induced by Botch are primarily mediated by changes in Notch signaling. The cellular retention in the VZ and SVZ induced by Botch knockdown is prevented when Notch signaling is inhibited by DN-MAML, indicating that knockdown of Botch upregulates Notch signaling. In cells overexpressing DN-MAML, shRNA-Botch does not restore normal cellular distribution. These results support the idea that shRNA-Botch acts upstream of the CBF-1 complex. If Botch and Notch were regulating the same process but not each other, we would have expected a partial rescue of the DN-MAML phenotype. Botch overexpression has no effect in cells in which Notch was already inhibited by DN-MAML. If Botch and Notch were regulating the same process but not each other, we would have expected a certain degree of synergistic effects between Botch and DN-MAML. Overexpression of NICD1 ablates the Botch overexpression phenotype, consistent with the notion that the actions of Botch are on the immature full-length form of Notch1 upstream of the S3 cleavage that generates NICD. Botch decreases neurosphere frequency similar to the γ-secretase inhibitor FXVIII, which prevents Notch signaling, and an in vitro differentiation assay indicates that overexpression of Botch promotes neuronal differentiation. Knockdown of Botch increases radial glia and increases glial differentiation, which can be rescued by γ-secretase inhibitor, DAPT. Taken together, these results imply that Botch regulates NSC self-renewal and differentiation, and promotes embryonic neurogenesis in opposition to Notch because all the effects of Botch overexpression are opposite to Notch signaling, and knockdown of Botch causes similar effects as Notch activation (Grandbarbe et al., 2003; Tanigaki et al., 2001; Yamamoto et al., 2001; Yoon et al., 2004).

**Botch Inhibits Notch by Regulating Notch Processing**

Botch is localized, in part, to the trans-Golgi where Notch is processed by S1 cleavage from a furin-like protease (Logeat et al., 1998). This S1 cleavage of the Notch receptor is thought to be required for Notch receptor maturation where Notch is ultimately cleaved into a TMIC domain and a NECD to form a functional receptor. Our findings indicate that Botch may interfere with Notch maturation by maintaining Notch in its full-length immature form. Evidence includes the observation that overexpression of Botch leads to accumulation of unprocessed immature full-length Notch and a corresponding decrease in the S1-cleaved ECD domain with decreased surface Notch1. Consistent with the possibility that Botch interferes with the furin-like cleavage of Notch is the observation that Botch blocks the furin cleavage of Notch in a similar manner as the furin inhibitor DEC-RVKR-CMK. This ultimately leads to a corresponding decrease in functional canonical Notch signaling. The failure to observe defects in the trafficking of other membrane receptors such as the glutamate NR2A or GluR1 receptors and the failure to observe defects in trafficking of Delta1 or Jagged1 indicate that Botch has a rather specific role in regulating Notch processing. It appears that Botch selectively regulates Notch trafficking to the cell surface via interference with the S1 furin-like cleavage of Notch. The exact role of Botch in this aspect of Notch signaling requires further investigation.
and identification of Botch’s biochemical mechanism of action. As recently reviewed by Kopan and Ilagan (2009), this aspect of Notch signaling is poorly understood. Further study of how Botch regulates the intracellular processing of Notch holds tremendous promise for understanding this aspect of Notch biology.

**Figure 7. Botch Promotes Neurogenesis by Regulating Cell Fate Choices**

(A) Representative images of neurosphere cultures.

(B) Quantification of neurosphere frequencies following expression of Botch or exposure to FXVIII. Values represent the mean ± SEM (n ≥ 3; **p < 0.01; ***p < 0.001, Student’s t test).

(C) Representative confocal images of cortex immunostained for GFP with DAPI and immunostained for BLBP following shRNA knockdown of Botch and expression of mtBotch.

(D) Quantification of normalized fluorescence intensity in (C). Values represent the mean ± SEM (n = 3; ***p < 0.001, Student’s t test).

(E) Representative confocal images of DAPI and immunostaining for GFAP and Tuj1 in cultured ganglionic eminence following expression of Botch and shRNA-Botch.

(F) Quantification of (E). Values represent the mean ± SEM (n = 6; *p < 0.05; ***p < 0.001, Student’s t test).

(G) Representative confocal images of DAPI and immunostaining for GFAP and Tuj1 in ganglionic eminence cultures with expression of shRNA-Botch in the presence or absence of DAPT.

(H) Quantification of (G). Values represent the mean ± SEM (n = 6; *p < 0.05; ***p < 0.001, Student’s t test).
**EXPERIMENTAL PROCEDURES**

**Plasmid Constructs and Vector-Based shRNA Constructs**

See Supplemental Experimental Procedures.

**In Situ Hybridization**

DIG-labeled anti-sense and sense RNA Botch probes were generated by T7 or T3 RNA polymerases using a template containing the mouse Botch cDNA clone (image number 4483043) as described (Blackshaw and Snyder, 1997). Whole-mount and sectioned embryos of specified stages were subjected to alkaline phosphatase-conjugated anti-DIG antibodies (Roche) to detect hybridized probes. Whole-mount images were acquired with a Zeiss Axiocam digital camera on a Zeiss Stemi SV11 microscope. For sections, images were taken using a Zeiss Axioskop compound microscope.

**Production of Antibodies**

See Supplemental Experimental Procedures.

**In Utero Injection and Electroporation**

All mice were housed and treated in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals under approval of the Johns Hopkins University Animal Use and Care Committee. DNA transfer into E13.5 CD-1 mouse brains in utero was performed as previously described (Mizutani et al., 2007) using a Nephogene CUY21EDT electroporator.

**Cell Line Cultures and Transfection**

HEK293, HeLa, C2C12, S2, and NIH 3T3 cells were obtained from the American Type Culture Collections. C2C12 cells stably expressing Notch1 (C2C12-N1) were provided by U. Lendahl (Karolinska Institute, Sweden) and have been described previously (Chapman et al., 2006). For C2C12 differentiation, 10% FBS was replaced with 2% horse serum (HS) in the culture medium for 4 days before immunostaining.

**CBF-1RE and NRE Luciferase Reporter Assay**

The coculture reporter assay was performed as described (Lindsell et al., 1995).

**Mouse Neuroprogenitor Cultures and Transfection**

Neurosphere and adherent progenitor cultures were established from E14.5 CD-1 mouse lateral and medial ganglionic eminences as described (Yoon et al., 2004).

**Quantitative Real-Time PCR**

See Supplemental Experimental Procedures.

**Immunoprecipitation Assays**

See Supplemental Experimental Procedures.

**Notch1-Botch-N-AP Binding Assays**

As described (Flanagan and Cheng, 2000), Botch-N-AP constructs were transiently transfected into HEK293 cells. Varied concentrations of Botch-N-AP fusion protein were incubated with an equal volume of Notch binding protein G beads at room temperature and assayed for AP activity.

**Cell Surface Biotinylation Labeling and Notch1-Jagged1 Binding Assays**

Biotin was used to label and isolate cell surface protein as described (Ladi et al., 2004).

**Immunoblot Analysis and Immunostaining**

See Supplemental Experimental Procedures.

**Golgi Sucrose Gradient Enrichment**

A Golgi isolation kit (Sigma-Aldrich) was used to isolate the Golgi fraction from E15.5 mouse forebrain by following the manufacturer’s instruction.

**Furin Cleavage Assay**

HEK293 cells were transfected with Flag-Notch1-GFP construct. The cell lysates were subjected to anti-GFP antibody immunoprecipitation with protein G Sepharose beads 24 hr later. The Flag-Notch1-GFP binding on protein G beads was first pretreated with AP or Botch-AP, and then treated with furin (New England BioLabs) and DMSO or furin with 50 μM DEC-RVKR-CMK (Enzo Life Sciences). Flag-Notch1-GFP at different time points of furin treatment was subject to immunoblot analysis with anti-Flag antibody. Furin cleavage was carried out at room temperature in total volume of 1 ml using 20 U of recombinant furin in 100 mM HEPES 7.5, 0.5% Triton X-100, and 1 mM CaCl2, as suggested by the manufacturer.

**Statistical Analysis**

Statistical analysis was performed using Prism or Excel software, and specific tests are noted in the text and figure legends. Unless otherwise noted, all error bars represent ±SEM, and significance was assessed as p < 0.05.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes five figures and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/j.devcel.2012.02.011.

**ACKNOWLEDGMENTS**

This work was supported by an American Heart Association Predoctoral Award to Z.C., USPHS FNS086010A to S.B., and McKnight Foundation Neuroscience of Brain Disorders Award, USPHS NS40809, DA00266, and MSCR81-0429 to V.L.D. T.M.D. is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases.

Received: November 30, 2010

Revised: October 25, 2011

Accepted: February 24, 2012

Published online: March 22, 2012

**REFERENCES**


